GlassScriptPhysician profile
Jeffrey B Armstrong
NPI 1336465814
$2,890.65
in general payments reported to CMS, 2019-2025
21 companies · $489 in 2025
The $489 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $102 · 2022: $449 · 2023: $1,062 · 2024: $788 · 2025: $489.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,340.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,339.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $619.04 | 2021-2025 | Trelegy Ellipta, Arexvy, Bexsero |
| Lilly USA, LLC | $462.86 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Abbvie INC. | $409.35 | 2022-2025 | Vraylar |
| Novo Nordisk INC | $393.10 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $275.34 | 2023-2025 | |
| Inspire Medical Systems, INC. | $100.60 | 2024-2025 | Inspire |
| Astrazeneca Pharmaceuticals LP | $96.21 | 2022-2025 | Airsupra, Farxiga |
| Exact Sciences Corporation | $71.24 | 2023-2025 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $58.75 | 2022-2024 | Jardiance |
| Genzyme Corporation | $53.66 | 2023 | |
| Sanofi-Aventis U.S. LLC | $51.21 | 2022-2023 | |
| Corcept Therapeutics | $50.11 | 2024-2025 | Korlym |
| Takeda Pharmaceuticals U.S.A., INC. | $48.86 | 2022-2023 | Glassia |
| Amgen INC. | $47.09 | 2023-2025 | Otezla, Repatha, Krystexxa |
| Bayer Healthcare Pharmaceuticals INC. | $32.66 | 2023 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verona Pharma, INC. | $23.71 | 2025 | Ohtuvayre |
| Kyowa Kirin, INC. | $23.57 | 2023 | Crysvita |
| Insightec,INC | $20.30 | 2023 | Exablate |
| Lundbeck LLC | $19.18 | 2024 | Rexulti |
| Sonex Health, INC. | $17.79 | 2025 | Sx-One Microknife |
| Medtronic, INC. | $16.02 | 2024 | Intellis Adaptivestim |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Armstrong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.